No.19



Similar documents
204 / CHEMISTRY & CHEMICAL INDUSTRY Vol.69-1 January

政策研ニュースNo27



untitled

Poket Manual H4_H1_130306

-2-



JAPAN MARKETING JOURNAL 111 Vol.28 No.32008

JAPAN MARKETING JOURNAL 113 Vol.29 No.12009

JAPAN MARKETING JOURNAL 110 Vol.28 No.22008

川崎学報57-4.indd

1

2 / 29


No.2

2 3


The Empirical Study on New Product Concept of the Dish Washer Abstract

JCOAL journal_Vol4(表紙)_0603

001

経済論集 46‐1(よこ)(P)/2.三崎

JAPAN MARKETING JOURNAL 123 Vol.31 No.32012

JAPAN MARKETING JOURNAL 115 Vol.29 No.32010

JAPAN MARKETING JOURNAL 110 Vol.28 No.22008


H1-H4*.ai


各科診療科長

【1】医薬品・医療機器等安全性情報 No

Microsoft Word - ????0803.docx

1 44

Microsoft Word - 荳ュ蟲カ諱オ

家族の将来

JAPAN MARKETING JOURNAL 123 Vol.31 No.32012

ave_vol.52.indd

k81p01-12

ルール&マナー集_社内版)_修正版.PDF

波野の宝・波野の地域課題

PowerPoint プレゼンテーション

文庫●注文一覧表2016c(7月)/岩波文庫



50, Q5 2


業務のご案内

橡Ⅵ 参考資料.PDF

9月_本土_地_h1_h4.ai

256-8月号.indd

2

Q&A Q Q Q Q Q Q Q Q Q Q

2

2


I I

97-00


1

13

01-02p_85.._......

2

表1-表4宅建99.indd

表1-表4宅建98.indd

表1-表4宅建101.indd

表1-表4宅建いわて-表紙.indd

CW3_AX056A01.indd

.T.C.Y._.E..

% 28.0% % 28.5% % 27.0% % 20.1% % ,831


2

CW3_A1083D05.indd

本文/年次報告  67‐107

32号 701062/きじ1

10西宮市立中央病院/本文

北九州高専 志遠 第63号/表紙・表4

特別プログラム

Ł\”ƒ

報告書(第2回NGO‐JICA)/はじめに・目次

P-12 P P-14 P-15 P P-17 P-18 P-19 P-20 P-21 P-22

ニューガラス100/100目次

untitled

program08.pdf



21世紀中国のシナリオ.PDF

アブニール49_入稿

食事編_表1_4_0508

Microsoft Word - 表紙資料2-4

Tf dvi

untitled

2 KEIO CARD NEWS vol.33

H1-H4_0906 [更新済み]

名称未設定-1

IF MR 63 IF 10 IF IF IF IF A4 IF IF IF 11 IF IF IF IF MR IF IF MR Drug Safety Update() IF

INDEX p01-02 p03-04 p05-07 p08 p09-10 p011 p12-16 p17-18 Audio Philosophy Integrated Amplifier Introduction A-30/A-10 Super Audio CD Player Introducti

‚æ01Łª“û†œ070203/1‘Í

J-D Lounge

01-全体表紙.PDF

宅建練馬表478号1_4ol [更新済み].eps

Transcription:

Views and Actions C

Points of View boxwhisker plot EU ICH http wwwinfopmdagojp n n n n n n No

n n n n n n pi pii pi pii pi pii n n n PKPD No

HTBD HTBD CD LHRH RS HTBD EGFR AT DMARD HTBD HTBD TNFα α HMGCoA TNFαLTα mg mg No

HIV n n n n n n n n No

n n n n N N N N N N N N N N N N No

Points of View No

No

No

Points of View CDROM Web n n No

n n n n No

n n No No

n n n HIV No

No

Points of View FIFA No IMS LifecyclePharmaprojects IMS Lifecycle No

ICH IMS Lifecycle ATC ATC N ATC J R G A B M L C M J G N L A M L C N C R G A B M L C N B M L C C N C C IMS World Review No

IMS LifecyclePharmaprojects No No

Points of View mg No

No

No

No No

B C HBVHCV HCV HCV HCV HCV IFNB HCV C IFN HCV HCV HCV No

C HCV HBV IFN IFN C IFN C HCV IFN HCV IFN IFN IFN HCV IFN IFN C C C C HCV C CC HCV C Q&A V C C ALTGPT No

IFN IFN IFN IFN IFN n n IFN IFN IFN IFN IFN n IFN IFN n IFN IFN n n IFN IFN IFN IFN IFN IFN IFN IFN No

PhPhPh Ph PhPh Pharmaprojects BiologicalBI Pharmaprojects No

Reichert mrna DNA mrna mrna RNAisiRNA sirna RNAi/siRNA ReichertJanice Met al Nature Biotechnology Vitravene fomivirsennovartisisis ICAM Macugen pegaptanibpfizergilead sciencevegf No

Gene Network No No M&A HS No SP Innovation in the pharmaceutical industry after the US patent reforms in thesan empirical study Review System for NDA Approval in the USA and Japan and their Performance of Review No

Status of Climical Trials & Approval Review in Japan Deloitte httpwwwcocokaradajp knowhow erabi index html NEDO NEDO JPM IMS No

No No The Review of New Drug Applications in JapanThe Decline in Approval Times After the Introduction of an Internalized Review System Drug Information Journal Vol Nop No No

OPIR Office of Pharmaceutical Industry Research TEL FAX httpwwwjpmaorjpopir